(Photo Courtesy: www.drugdiscovery.com)
The company's latest report states that the liver cancer pipeline contains a large amount of first-in-class innovation, contrasting heavily to the market landscape, which has shown little in the way of therapeutic innovation in recent years, with the exception of Nexavar (sorafenib).
While liver cancer is the sixth most common cancer worldwide, its poor prognosis makes it the second leading cause of cancer death.
Rising prevalence in developed economies and the success of targeted oncology therapies are factors driving interest in drug development.
Mr Joshua Libberton, analyst, GBI Research, says: "The liver cancer treatment market is highly segmented in terms of its needs, as early-stage patients have access to curative therapies, such as surgical resection, and have a relatively strong outlook.
"However, for patients diagnosed in later stages, who represent the majority of the patient population, treatment is limited to chemotherapy, which does not provide an appreciable benefit to Overall Survival (OS), and the targeted therapy Nexavar, which does offer a limited OS benefit."